First to market patent drugs and profits

When bringing a new drug to the market through the patent process time to market, and the industrial competition saturation are the two biggest contributors in determining profitability (Maresch, Fink, & Harms, 2016). Empirical research performed on patent companies found that first to market alone is not responsible for higher profits (Maresch, Fink, & Harms, 2016). Higher yields were discovered when observing newly patent products in high emerging competition industries (Maresch, Fink, & Harms, 2016). Along the life of the patent data revealed companies loss money in the latter years of the legal protection (Maresch, Fink, & Harms, 2016). In emerging pathological discoveries the competition is higher and profits are higher for companies that are first to market. The problem for many companies looking to provide vaccination or drugs to address illness outbreaks is the relevance of the drug when factoring cost of research and development. Bringing a new drug to the market just in time would be ideal to cut cost of R&D and yield profits of peak demand. Estimating any phenomena outbreak is a cause for ethical investigation considering you must convince investors of probability to a specific epidemic occurrence. Reference Maresch, D., Fink, M., & Harms, R. (2016). When patents matter: The impact of competition and patent age on the performance contribution of intellectual property rights protection. Technovation, 57-58, 14-20. doi:10.1016/j.technovation.2015.11.009